Please login to the form below

Not currently logged in
Email:
Password:

Bridion

This page shows the latest Bridion news and features for those working in and with pharma, biotech and healthcare.

FDA approvals hit 19-year high

FDA approvals hit 19-year high

Among these, the FDA highlighting Merck &Co's neuromuscular blockade reversal agent Bridion (sugammadex), Pfizer's CD4/6 inhibitor Ibrance (palbociclib) for breast cancer and Boehringer Ingelheim's Praxbind (idarucizumab), a

Latest news

  • Merck finally bags FDA approval for Bridion Merck finally bags FDA approval for Bridion

    The US FDA has approved Merck &Co's Bridion to reverse the effects of neuromuscular blockade induced by muscle relaxants used during surgery. ... Merck said it plans to launch Bridion in January and will announce Bridion's price at that time.

  • At long last, Merck gets FDA panel backing for Bridion At long last, Merck gets FDA panel backing for Bridion

    After several knockbacks, Merck &Co has finally moved a key step closer to securing FDA approval for its muscle relaxant reversal agent Bridion. ... Bridion (sugammadex) was first rejected by the FDA in 2008, and was turned down once again in 2013.

  • Merck faces another Bridion knockback Merck faces another Bridion knockback

    Merck maintains that Bridion provides faster and more complete reversal of neuromuscular blockade than the older drugs and has a lesser effect on heart rate. . ... Bridion was acquired by Merck when it took over Schering-Plough in 2009.

  • R&D in the firing line as Merck & Co axes 8,500 jobs R&D in the firing line as Merck & Co axes 8,500 jobs

    Recent setbacks in Merck's late-stage pipeline include a delay in US approval of anaesthesia drug Bridion (sugammadex) and an FDA rejection for insomnia candidate suvorexant, while the company has

  • FDA rejects Merck muscle relaxant drug once again FDA rejects Merck muscle relaxant drug once again

    Regulator still has hypersensitivity concerns about Bridion. Merck &Co's muscle relaxant Bridion has been available in the EU for five years, but the company has once again failed to convince ... reactions that was requested by the FDA when it turned

More from news
Approximately 6 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics